Diabetes mellitus (DM) is a metabolic syndrome that’s spreading like an epidemic all through the world with none differentiation of races and ethnic teams and has grow to be the reason for loss of life worldwide. It’s characterised by excessive ranges of glucose within the blood and has differing kinds labeled on the premise of various pathophysiology.
Kind 1 diabetes or insulin-dependent diabetes is characterised by insulin insufficiency resulting from autoimmune dysfunction. Kind 2 diabetes or non-insulin-dependent diabetes outcomes from the mixture of resistance to insulin motion or/and insufficient insulin secretion. Gestational diabetes (GDM) is outlined as hyperglycemia resulting from insulin resistance throughout being pregnant.
Different sorts embrace the monogenic sort of DM resembling neonatal diabetes mellitus (NDM), maturity-onset diabetes of younger (MODY), and diabetes in metabolic syndrome. Diabetes is identified by standards given by American Diabetes Affiliation (ADA) for various checks like fasting plasma glucose take a look at and hemoglobin A1c take a look at.
It’s characterised by polydipsia, polyphagia, hyperglycemia, and glucosuria. Diabetes mellitus is managed by medicines however many research have confirmed that consumption of explicit meals results in decreased glucose ranges in diabetic sufferers.
The bioactive elements in these seeds like chlorogenic acid in sunflower seeds and secoisolariciresinol diglucosoid are concerned within the therapy of insulin resistance or insulin manufacturing. Seeds like sunflower and flax seeds have a job within the discount of glucose ranges and can be utilized to deal with sort 2 diabetes.
In numerous research, totally different quantities of those seed extracts have been consumed by rats and people and it resulted in higher glycemic management, which gives info that these seeds have anti-diabetic properties.
Sulfonylureas for Therapy of Periodontitis-Diabetes Comorbidity-Associated Issues: Killing Two Birds With One Stone
Periodontitis is without doubt one of the most prevalent oral inflammatory ailments resulting in tooth loss and oral well being issues in adults. Periodontitis primarily impacts periodontal tissue by affecting the host immune system and bone homeostasis. Furthermore, periodontitis is related to varied systemic ailments.
Diabetes is a metabolic illness with systemic results. Each periodontitis and diabetes are frequent inflammatory ailments, and comorbidity of two ailments is linked to exacerbation of the pathophysiology of each ailments. Since bacterial dysbiosis is principally accountable for periodontitis, antibiotics are extensively used medication to deal with periodontitis in clinics.
Nevertheless, the outcomes of antibiotic remedies in periodontitis are usually not passable. Due to this fact, the applying of anti-inflammatory medication together with antibiotics could possibly be a therapy choice for periodontitis-diabetes comorbidity. Anti-diabetic medication normally have anti-inflammatory properties and have proven useful results on periodontitis.
Sulfonylureas, insulin secretagogues, are the earliest and most generally used oral hypoglycemic medication used for type-2 diabetes. Research have discovered that sulfonylurea medication can play a sure position within the mitigation of periodontitis and irritation.
This text evaluations the consequences of sulfonylurea medication on the mitigation of periodontitis-diabetes comorbidity-related irritation, bone loss, and vascular development in addition to the concerned molecular mechanisms. We focus on the potential of a brand new utility of sulfonylureas (previous drug) to deal with periodontitis-diabetes comorbidity.
The Validity of the American Diabetes Affiliation’s Diabetes Danger Check in a Saudi Arabian Inhabitants
Introduction The prevalence of sort 2 diabetes (T2D) is rising worldwide. This examine aimed to evaluate the sensitivity and specificity of the American Diabetes Affiliation (ADA) and america Facilities for Illness Management and Prevention’s diabetes threat take a look at in figuring out Saudi Arabian sufferers prone to creating T2D.
Strategies We carried out a one-month cross-sectional examine that included sufferers older than 18 years who visited main care services for any well being concern in Riyadh Metropolis, Saudi Arabia. We used the Arabic language model of the ADA Prediabetes Danger Check questionnaire, a validated and dependable device, to gather information.
For this examine, we analyzed the information utilizing IBM SPSS Statistics for Home windows, model 24.0 (IBM Corp., Armonk, New York). Furthermore, we calculated sensitivity and specificity, constructive predictive values (PPV), destructive predictive worth (NPV), the realm beneath the curve (AUC), and Youden’s index.
Outcomes A complete of 180 individuals have been included within the examine (121 ladies and 59 males; imply age = 45 years). The ADA Prediabetes Danger Check sensitivity was 78.9, specificity was 82, PPV was 32, and NPV was 76. Youden’s index was 60.9 and the AUC was 0.6.
Conclusion The ADA prediabetes threat evaluation device is extremely delicate and particular for figuring out the illness. It’s a dependable and legitimate device that has not but been applied to a fantastic extent in Saudi Arabia. Due to this fact, future work ought to examine the device’s effectiveness in threat evaluation in extra native Saudi Arabian communities.
This cross-sectional analytical examine concerned sufferers with tbl2DM aged ≥ 18 years who used metformin for a minimum of three months. The serum VitB12 was quantified on a chemiluminescent enzyme immunoassay analyzer utilizing Cobas e 801 module, Roche, and VitB12 deficiency was outlined as serum VitB12 stage of ≤ 145 pmol/L. All information have been obtained from the sufferers’ digital medical data.
Muscle Infarction Following Fast Glycemic Management in a Affected person With Diabetes-Related Microvascular Illness
We report a case of a 40-year-old African male with a historical past of diabetes mellitus with a number of microvascular problems, having lately initiated insulin therapy with a speedy decline in glycosylated hemoglobin (HbA1c) focus. The affected person offered with a sudden onset of proper thigh ache and swelling not related to trauma. Blood work revealed elevated inflammatory markers.
AAV1-Luc Control Virus |
AAV-321 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
Description: Luciferase control virus of AAV serotype 1. |
AAV3-Luc Control Virus |
AAV-323 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
Description: Luciferase control virus of AAV serotype 3. |
AAV4-Luc Control Virus |
AAV-324 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
Description: Luciferase control virus of AAV serotype 4. |
AAV5-Luc Control Virus |
AAV-325 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
Description: Luciferase control virus of AAV serotype 5. |
AAV6-Luc Control Virus |
AAV-326 |
Cell Biolabs |
50 ?L |
EUR 1221.6 |
Description: Luciferase control virus of AAV serotype 6. |
Lenti-hTERT Antisense virus |
G201 |
ABM |
10 ml |
EUR 882 |
Lenti-hTERT-Neo Virus |
G204 |
ABM |
10 ml |
EUR 973.2 |
Lenti-Myc T58A Virus |
G217 |
ABM |
10 ml |
EUR 973.2 |
Lenti-p53 siRNA Virus |
G219 |
ABM |
10 ml |
EUR 973.2 |
Lenti-Ras V12 Virus |
G221 |
ABM |
10 ml |
EUR 973.2 |
Lenti-Rb siRNA Virus |
G223 |
ABM |
10 ml |
EUR 973.2 |
NF-κB Reporter (Luc) - HCT116 Cell Line |
60623 |
BPS Bioscience |
2 vials |
EUR 1095 |
Description: NF-B luciferase reporter construct is stably integrated into the genome of HCT-116 cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF-κB-luciferase/HCT-116 cell line is suitable for monitoring the activity of NF-κB signaling in response to stimulants such as the cytokines TNF and IL-1β, pathogen-associated molecular pattern (PAMP) (i.e. flagellin) or endogenous damage-associated molecular pattern (DAMP) molecules (i.e. NOD1 ligand) (see application references). It is also suitable for establishing cell-based screens for inhibitors that target specific NF-κB stimulating molecules. This cell line can be further modified to allow investigation of downstream NF-κB activities as a result of targeted genetic mutation(s). |
Foxp3 Reporter (Luc) - Jurkat Recombinant Cell Line |
60628 |
BPS Bioscience |
2 vials |
EUR 7645 |
Description: Human Foxp3 luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by a human Foxp3 promoter and an enhancer-like conserved noncoding sequence upstream of the Foxp3 promoter. |
NF-κB reporter (Luc) - HEK293 Cell line |
60650 |
BPS Bioscience |
2 vials |
EUR 1365 |
Description: The NF-κB reporter (Luc) HEK293 cell line is designed to monitor nuclear factor Kappa B (NF-κB) activity. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or agonists of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. The cell line has been functionally validated in response to human TNF-α, IL-1β, and IL-17. |
STAT5 Reporter (Luc) - Ba/F3 Cell line |
79772 |
BPS Bioscience |
2 vials |
EUR 2275 |
Description: The STAT5 Reporter (Luc)-Ba/F3 cell line is designed for monitoring STAT5 signal transduction pathways. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by cytokines or growth factors, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene. |
STAT3 Reporter (Luc) - HEK293 Cell line (Puromycin) |
79800-P |
BPS Bioscience |
2 vials |
EUR 3730 |
Description: The STAT3 Reporter (Luc)-HEK293 cell line is designed for monitoring STAT3 signal transduction pathway. It contains a firefly luciferase gene driven by STAT3 response elements located upstream of the minimal TATA promoter. After activation by cytokines and growth factors, endogenous STAT3 binds to the DNA response elements, inducing transcription of the luciferase reporter gene. |
IRF Reporter (Luc) - THP-1 Cell line |
79858 |
BPS Bioscience |
2 vials |
EUR 1810 |
Description: The Interferon Regulatory Factor (IRF) reporter (Luc)-THP-1 cell line is designed to study the activation and signaling of Cytosolic DNA Sensors (CDS) in human monocytic cell line THP-1. It contains a firefly luciferase gene driven by multimerized ISRE (Interferon Stimulated Response Element) located upstream of the minimal TATA promoter. _x000D_The cGAS-STING pathway acts to detect cytosolic DNA and induce an immune response. Briefly, upon binding DNA, the protein cGAS (cyclic GMP-AMP Synthase) triggers reaction of GTP and ATP to form cGAMP. cGAMP binds to STING (Stimulator of Interferon Genes) which triggers phosphorylation of IRF3 via TBK1. IRF3 can then bind to interferon-stimulated responsive elements (ISRE) in the nucleus and leads to IFN-α/β production. The IRF reporter (Luc)-THP-1 cell line is highly responsive to STING and CDS ligands. |
Bald Lentiviral Pseudovirion (Luc-eGFP Dual Reporter) |
79988 |
BPS Bioscience |
500 µl x 2 |
EUR 795 |
Description: The bald lentiviral pseudovirion was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) as the reporters, driven by a CMV promoter. The bald lentiviral pseudovirion can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors._x000D_ |
Lenti-Bmi1 Virus, High Titer |
LV608 |
ABM |
5 x 20 ul |
EUR 1825.2 |
Lenti-CDK4 Virus, High Titer |
LV609 |
ABM |
5 x 20 ul |
EUR 1825.2 |
Lenti-hTERT Virus, High Titer |
LV615 |
ABM |
5 x 20 ul |
EUR 1825.2 |
Lenti-EF1α-hTERT Virus |
G706 |
ABM |
10 ml |
EUR 1094.4 |
PAI-1 Reporter (Luc) - Mv1 Lu Cell Line |
60544 |
BPS Bioscience |
2 vials |
EUR 3595 |
Description: PAI-1 Reporter (Luc)-Mv1 Lu cell line is designed for monitoring transforming growth factor β (TGF-β)-induced plasminogen activator inhibitor-1 (PAI-1) expression. Transforming growth factor-β (TGF-β) is a potent regulator of cellular differentiation, proliferation, migration, and protein expression._x000D__x000D_PAI-1 Reporter (Luc) -Mv1 Lu cell line contains a firefly luciferase gene under the control of PAI-1 responsive elements stably integrated into Mv1 Lu (NBL-7) cells, showing TGF-β pathway response. This cell line is validated for the TGF-β response to the induction of PAI-1 gene expression through luciferase activity. _x000D_ |
NF-κB Reporter (Luc) - CHO-K1 Cell Line |
60622 |
BPS Bioscience |
2 vials |
EUR 1095 |
Description: An NF-κB luciferase reporter construct is stably integrated into the genome of CHO-K1 cells. The firefly luciferase gene is controlled by the NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF-κB-luciferase / CHO-K1 cell line is suitable for monitoring the activity of NF-κB transcription factor through luminescence readout.). This cell line responds to human cytokine IL-1β, responds moderately to human TNF, and does not respond to human IFN-λ (2 µg/ml). Reducing the amount of serum during incubation period may increase the sensitivity to cytokines. Since CHO-K1 cells do not express endogenous human proteins, this cell line provides an excellent platform to enable exogenous expression of a protein of interest to study its downstream effect on NF-κB signaling. |
NF-κB Reporter (Luc) - A549 Stable Cell Line |
60625 |
BPS Bioscience |
2 vials |
EUR 1915 |
Description: NF-κB luciferase reporter construct is stably integrated into the genome of A549 cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. |
NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line |
60651 |
BPS Bioscience |
2 vials |
EUR 2340 |
Description: NF-κB luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by 4 copies of NF-kB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. |
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter) |
78172-1 |
BPS Bioscience |
100 µl |
EUR 835 |
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G |
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter) |
78172-2 |
BPS Bioscience |
500 µl x 2 |
EUR 4195 |
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G |
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter) |
78204-1 |
BPS Bioscience |
100 µl |
EUR 835 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. |
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter) |
78204-2 |
BPS Bioscience |
500 µl x 2 |
EUR 4195 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. |
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter) |
78205-1 |
BPS Bioscience |
100 µl |
EUR 835 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H |
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter) |
78205-2 |
BPS Bioscience |
500 µl x 2 |
EUR 4195 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H |
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter) |
78206-1 |
BPS Bioscience |
100 µl |
EUR 835 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G |
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter) |
78206-2 |
BPS Bioscience |
500 µl x 2 |
EUR 4195 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G |
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter) |
78215-1 |
BPS Bioscience |
100 µl |
EUR 900 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility. |
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter) |
78215-2 |
BPS Bioscience |
500 µl x 2 |
EUR 4510 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility. |
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter) |
78614-1 |
BPS Bioscience |
100 µl |
EUR 860 |
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951). |
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter) |
78614-2 |
BPS Bioscience |
500 µl x 2 |
EUR 4320 |
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951). |
NF-κB reporter (Luc) - NIH/3T3 Cell line |
79469 |
BPS Bioscience |
2 vials |
EUR 1900 |
Description: The NF-κB reporter (Luc)-NIH/3T3 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. |
NF- κB Reporter (Luc) - THP-1 Cell Line |
79645 |
BPS Bioscience |
2 vials |
EUR 1900 |
Description: The NF-κB reporter (Luc)-THP-1 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. |
STAT5 Reporter (Luc)- U937 Cell Line (GM-CSF) |
79941 |
BPS Bioscience |
2 vials |
EUR 1980 |
Description: The STAT5 Reporter (Luc)-U937 cell line is designed for monitoring STAT5 signal transduction pathway in the U937 cell line. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by GM-CSF, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene. |
NF- κB Reporter (Luc) - Raw 264.7 Cell line |
79978 |
BPS Bioscience |
2 vials |
EUR 2045 |
Description: The NF-κB reporter (Luc)-Raw 264.7 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. |
Steady-Luc Firefly HTS Assay Kit (10x100 ml) |
30028-3 |
Biotium |
1KIT |
EUR 3774 |
Description: Minimum order quantity: 1 unit of 1KIT |
Human BM88 Differentiation Reporter (pGreenZeo, Virus) |
SR10021VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse Camk2a Differentiation Reporter (pGreenZeo, Virus) |
SR10022VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse GAD67 Differentiation Reporter (pGreenZeo, Virus) |
SR10023VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Rat NSE Differentiation Reporter (pGreenZeo, Virus) |
SR10024VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse MBP Differentiation Reporter (pGreenZeo, Virus) |
SR10026VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human Opsin Differentiation Reporter (pGreenZeo, Virus) |
SR10027VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human Insulin Differentiation Reporter (pGreenZeo, Virus) |
SR10028VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human LCK Differentiation Reporter (pGreenZeo, Virus) |
SR10032VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Rat Nestin Differentiation Reporter (pGreenZeo, Virus) |
SR10034VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human Nestin Differentiation Reporter (pGreenZeo, Virus) |
SR10035VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse ALBP Differentiation Reporter (pGreenZeo, Virus) |
SR10036VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human NGN3 Differentiation Reporter (pGreenZeo, Virus) |
SR10037VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human PDX1 Differentiation Reporter (pGreenZeo, Virus) |
SR10039VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human Osteocalcin Differentiation Reporter (pGreenZeo, Virus) |
SR1003VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse PDX1 Differentiation Reporter (pGreenZeo, Virus) |
SR10040VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human MAP2 Differentiation Reporter (pGreenZeo, Virus) |
SR10047VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human FABP7 Differentiation Reporter (pGreenZeo, Virus) |
SR10048VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human ACTC Differentiation Reporter (pGreenZeo, Virus) |
SR10049VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human B29 Differentiation Reporter (pGreenZeo, Virus) |
SR1004VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse Myogenin Differentiation Reporter (pGreenZeo, Virus) |
SR10050VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human GFAP Differentiation Reporter (pRedZeo, Virus) |
SR10051VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse B29 Differentiation Reporter (pGreenZeo, Virus) |
SR1005VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human NKX2.5 Differentiation Reporter (pGreenZeo, virus) |
SR10067VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse CD8 Differentiation Reporter (pGreenZeo, Virus) |
SR1006VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse CD68 Differentiation Reporter (pGreenZeo, Virus) |
SR1008VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human CD2 Differentiation Reporter (pGreenZeo, Virus) |
SR1009VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Oct4 CR4-pGreenFire Response Reporter (virus) |
SR20070-VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 882 |
|
Mouse Actc Differentiation Reporter (pGreenZeo, Virus) |
SR10010VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human Tnnt2 Differentiation Reporter (pGreenZeo, Virus) |
SR10012VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse Tnnt2 Differentiation Reporter (pGreenZeo, Virus) |
SR10013VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse SM22a Differentiation Reporter (pGreenZeo, Virus) |
SR10014VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human GFAP Differentiation Reporter (pGreenZeo, Virus) |
SR10015VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse GFAP Differentiation Reporter (pGreenZeo, Virus) |
SR10016VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human CD11b Differentiation Reporter (pGreenZeo, Virus) |
SR10017VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse EMR1 Differentiation Reporter (pGreenZeo, Virus) |
SR10018VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse Col2a1 Differentiation Reporter (pGreenZeo, Virus) |
SR1001VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse CD44 Differentiation Reporter (pGreenZeo, Virus) |
SR10020VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
NF-kB/293/GFP-Luc Transcriptional Reporter Cell Line |
TR860A-1 |
SBI |
>2 x 10^6 cells |
EUR 3915.6 |
|
Myc Reporter (Luc) - HCT116 Cell Line (Myc Signaling Pathway) |
60520 |
BPS Bioscience |
2 vials |
EUR 2175 |
Description: The Myc Reporter - HCT116 cell line contains the firefly luciferase gene under the control of Myc responsive elements stably integrated into HCT116 cells, a human colon cancer cell line. HCT116 contains a mutated beta-catenin which leads to the accumulation of β-catenin and constitutive activation of downstream Myc that induces the expression of Myc luciferase reporter. The cell line is validated for the inhibition of the expression of Myc luciferase reporter. |
GITR / NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line |
60546 |
BPS Bioscience |
2 vials |
EUR 10175 |
Description: This cell line expresses a surface human GITR (glucocorticoid-induced TNFR family related gene; TNFRSF18; CD357) and an NF-κB luciferase reporter construct that are stably integrated into the genome of Jurkat T-cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. The cells have been validated using purified human GITRL and anti-GITR neutralizing antibody. |
CD40/NF-κB Reporter (Luc) - HEK293 Stable Cell Line |
60626 |
BPS Bioscience |
2 vials |
EUR 6825 |
Description: Recombinant HEK293 cell line expressing full length human CD40 (Tumor necrosis factor receptor superfamily member 5; TNFRSF5). Expression is confirmed by real-time qPCR and Western Blot. This NF-κB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD40 ligand, NF-κB transcription factor binds to the DNA response elements to induce transcription of the luciferase gene. _x000D_ |
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter) |
78028-1 |
BPS Bioscience |
100 µl |
EUR 900 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter) |
78028-2 |
BPS Bioscience |
500 µl x 2 |
EUR 4510 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
GLP-1R/CRE (Luc) Reporter - HEK293 Recombinant Cell Line |
78176 |
BPS Bioscience |
2 vials |
EUR 10105 |
Description: Recombinant HEK293 cells expressing firefly luciferase gene under the control of cAMP response element (CRE) with constitutive expression of human GLP-1R (Glucagon-like peptide 1 receptor; accession number BC113493)._x000D_GLP-1R, a member of the class B family of G protein-coupled receptors (GPCRs) primarily found in pancreatic β cells, is activated by a peptide hormone, glucagon-like peptide 1 (GLP-1) that is secreted from intestinal L-cells after nutrient ingestion. GLP-1R plays an important role in controlling blood sugar level by enhancing glucose-stimulated insulin secretion, so various research efforts have focused on the regulation of the GLP-1R mediated signaling pathway as a therapeutic approach to diabetes. |
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter) |
78348-1 |
BPS Bioscience |
100 µl |
EUR 900 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951). |
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter) |
78348-2 |
BPS Bioscience |
500 µl x 2 |
EUR 4510 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951). |
Lenti-Myc T58A Virus, High Titer |
LV618 |
ABM |
5 x 20 ul |
EUR 1825.2 |
Lenti-p53 siRNA Virus, High Titer |
LV619 |
ABM |
5 x 20 ul |
EUR 1825.2 |
Lenti-Ras V12 Virus, High Titer |
LV620 |
ABM |
5 x 20 ul |
EUR 1825.2 |
Lenti-Rb siRNA Virus, High Titer |
LV621 |
ABM |
5 x 20 ul |
EUR 1825.2 |
Lenti-hTERT-Neo Virus, High Titer |
LV622 |
ABM |
5 x 20 ul |
EUR 1825.2 |
Lenti-HPV-16 E6/E7 Virus |
G268 |
ABM |
10 ml |
EUR 882 |
Rrad 3'UTR Luciferase Stable Cell Line |
TU219725 |
ABM |
1.0 ml |
Ask for price |
Rrad 3'UTR GFP Stable Cell Line |
TU168183 |
ABM |
1.0 ml |
Ask for price |
Rrad 3'UTR GFP Stable Cell Line |
TU269725 |
ABM |
1.0 ml |
Ask for price |
Rrad 3'UTR Luciferase Stable Cell Line |
TU118183 |
ABM |
1.0 ml |
Ask for price |
RRAD 3'UTR GFP Stable Cell Line |
TU072380 |
ABM |
1.0 ml |
EUR 1672.8 |
RRAD 3'UTR Luciferase Stable Cell Line |
TU022380 |
ABM |
1.0 ml |
EUR 1672.8 |
RRAD Antibody |
CSB-PA233809-100ul |
Cusabio |
100ul |
EUR 379.2 |
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
RRAD Antibody |
1-CSB-PA248209 |
Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100 |
RRAD Antibody |
1-CSB-PA003910 |
Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000 |
RRAD siRNA |
20-abx932133 |
Abbexa |
|
|
|
RRAD Antibody |
1-CSB-PA779820 |
Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
RRAD antibody |
70R-50359 |
Fitzgerald |
100 ul |
EUR 292.8 |
Description: Purified Polyclonal RRAD antibody |
RRAD antibody |
70R-5797 |
Fitzgerald |
50 ug |
EUR 560.4 |
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
RRAD antibody |
70R-5798 |
Fitzgerald |
50 ug |
EUR 560.4 |
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
RRAD Peptide |
43-008P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: RRAD Peptide |
RRAD Antibody |
37229-100ul |
SAB |
100ul |
EUR 302.4 |
RRAD Antibody |
CSB-PA233809- |
Cusabio |
each |
EUR 402 |
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
GR-GAL4 Reporter (Luc)-HEK293 Cell Line (Glucocorticoid Receptor Pathway) |
60655 |
BPS Bioscience |
2 vials |
EUR 2275 |
Description: The Glucocorticoid Receptor Pathway GAL4 Reporter (Luc) - HEK293 Cell Line contains a_x000D_firefly luciferase gene under the control of glucocorticoid receptor ligand binding domain that is_x000D_fused to the DNA binding domain (DBD) of GAL4 (GAL4 DBD-GR) stably integrated into_x000D_HEK293 cells. This fusion construct activates firefly luciferase expression under the control of a_x000D_multimerized GAL4 upstream activation sequence (UAS). This allows for specific detection of_x000D_glucocorticoid-induced activation of the glucocorticoid receptor without the need for individual_x000D_transcriptional targets and with low cross-reactivity for other nuclear receptor pathways. This cell_x000D_line is validated for response to stimulation of dexamethasone and to the treatment with_x000D_mifepristone, an inhibitor of the glucocorticoid signaling pathway. |
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter) |
78112-1 |
BPS Bioscience |
100 µl |
EUR 875 |
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_ |
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter) |
78112-2 |
BPS Bioscience |
500 µl x 2 |
EUR 4405 |
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_ |
Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter) |
78218-1 |
BPS Bioscience |
100 µl |
EUR 835 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility. |
Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter) |
78218-2 |
BPS Bioscience |
500 µl x 2 |
EUR 4195 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility. |
GAS Reporter (Luc) - HeLa Cell Line (IFNγ/JAK/STAT1 Pathway) |
79041 |
BPS Bioscience |
2 vials |
EUR 1810 |
Description: The GAS reporter (Luc)-HeLa cell line is designed to monitor the activity of interferon gamma-induced signal transduction pathways in cultured cells by measuring activated STAT1 homodimers. It contains a firefly luciferase gene driven by three copies of the interferon gamma-activated sites (GAS) located upstream of the minimal TATA promoter. IFNγ first binds to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2). Two STAT1 molecules associate with this ligand-activated receptor complex and are activated by phosphorylation to form active homodimer. The active STAT1 homodimers translocate to the nucleus where they bind interferon gamma-activated sites (GAS) in the promoter of IFNγ inducible genes, including luciferase reporter gene. |
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter) |
79982-1 |
BPS Bioscience |
100 µl |
EUR 1075 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_ The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_ |
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter) |
79982-2 |
BPS Bioscience |
500 µl x 2 |
EUR 8110 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_ The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_ |
Mouse Alpha-Tubulin Differentiation Reporter (pGreenZeo, Virus) |
SR10025VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human SPP-1 Differentiation Reporter (pGreenZeo, Virus) |
SR1002VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human Keratin 14 Differentiation Reporter (pGreenZeo, Virus) |
SR10038VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human Doublecortin (DCX) Differentiation Reporter (pGreenZeo, Virus) |
SR10041VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human HLA-DRa Differentiation Reporter (pGreenZeo, Virus) |
SR1007VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human MLC-2v Differentiation Reporter (pGreenZeo, Virus) |
SR10011VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Human GFAP Differentiation Reporter (pGreenZeo, Virus) Puro |
SR10015VA-P |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Mouse IBA-1 Differentiation Reporter (pGreenZeo, Virus) |
SR10019VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 906 |
|
Lenti-EF1α-hTERT Virus, High Titer |
LV616 |
ABM |
5 x 20 ul |
EUR 2068.8 |
A presumptive prognosis of pyomyositis was made and the affected person was handled with intravenous antibiotics with no enchancment. Diabetic muscle infarction was then thought of and confirmed by magnetic resonance imaging of the affected thigh. As with retinopathy and neuropathy deterioration which were described as secondary to an aggressive glycemic management, it’s doable that muscle myonecrosis could have been consequent to the speedy HbA1c normalization.